Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - RMD open, 2018 - rmdopen.bmj.com
Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
[引用][C] Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - RMD Open, 2018 - cir.nii.ac.jp
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with
allopurinol in adults with gout: a phase IIa, open-label study | CiNii Research CiNii 国立情報学 …
allopurinol in adults with gout: a phase IIa, open-label study | CiNii Research CiNii 国立情報学 …
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
R Fleischmann, P Winkle, JN Miner, X Yan… - RMD …, 2018 - pubmed.ncbi.nlm.nih.gov
Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
[HTML][HTML] Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - RMD …, 2018 - ncbi.nlm.nih.gov
Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - RMD Open, 2018 - europepmc.org
Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
[PDF][PDF] Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - academia.edu
ABSTRACT Objectives Verinurad (RDea3170) is a high affinity, selective uric acid
transporter (URat1) inhibitor indevelopment for treating gout and asymptomatic …
transporter (URat1) inhibitor indevelopment for treating gout and asymptomatic …
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
R Fleischmann, P Winkle, JN Miner, X Yan, L Hicks… - RMD Open, 2018 - europepmc.org
Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …